Obesity
Conditions
Keywords
Dietary Supplements, AI-guided prescriptions, Genetic profiling, Metabolic profiling
Brief summary
Obesity, a chronic disease characterized by excessive fat accumulation, significantly impacts health. Genetic factors influence the development of obesity by affecting behavioral, dietary habits, and metabolic processes. This study investigated whether dietary supplements (DS), personalized through genetic and metabolic profiling, could enhance weight loss when combined with physical activity and dietary changes. The objective was to compare the efficacy of standard physician-guided DS prescriptions with AI-guided DS prescriptions in promoting weight loss in obese patients. The hypothesis was that AI-guided DS prescriptions, utilizing detailed genetic and metabolic data, would be more effective in promoting weight loss than standard physician-guided DS prescriptions. This was a 6-month randomized, controlled pilot clinical trial with an additional 6-month follow-up. Participants were healthy individuals aged 40-60 years with a BMI of 25 or greater. Participants were excluded if they had significant medical conditions or recent changes in medication or supplements. They were randomly assigned to either the control group (physician-guided DS prescriptions) or the AI-guided group (AI-determined DS prescriptions). The AI system developed by Triangel Scientific analyzed genetic, metabolic, and biochemical data to personalize treatment. Baseline measurements included comprehensive metabolic panels, genetic testing, metabolomic profiling, and detailed patient history
Interventions
OTHERControl Group
Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
OTHERAI-Guided Group
Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Sponsors
Center of New Medical Technologies
S.LAB (SOLOWAYS)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Healthy participants aged between 40 and 60 years. * BMI of 25 or greater and no more than a 3% change in body mass within the last three months.
Exclusion criteria
* Individuals who have taken any prescribed medications or dietary supplements in the two weeks prior to the study. * Those with a clinically significant history of major digestive, liver, kidney, cardiovascular, hematological diseases, diabetes, gastrointestinal disorders, or any other serious acute or chronic medical conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage change in body weigh | 180 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent change in high-sensitivity C-reactive | 180 days | — |
| Percent change in fasting glucose | 180 days | — |
| Percent change in insulin | 180 days | — |
| Percent change in total cholesterol | 180 days | — |
| Change in BMI | 180 days | — |
| Percent change in high density lipoprodeids | 180 days | — |
| Percent change in triglycerides | 180 days | — |
| Appetite ratings using visual analogue scale change | 180 days | The scale has minimum of 0 - no appetite and 10 as a good appetite |
| Percent change in Low density lipoproteids | 180 days | — |
Countries
Russia
Outcome results
None listed